Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (391-400 of 404) with videos related to

Pageof 41
Sort By:
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
Journal of Hepatology|November 24, 2015
FibroGENE: A gene-based model for staging liver fibrosisMohammed Eslam, Ahmed M Hashem, Manuel Romero-Gomez, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Nature Communications|March 6, 2015
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver diseaseMohammed Eslam, Ahmed M Hashem, Reynold Leung, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypesMohammed Eslam, Alessandra Mangia, Thomas Berg, et al.
Scientific Reports|February 7, 2019
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanismsRasha El Sharkawy, Ali Bayoumi, Mayada Metwally, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Pageof 41

Showing results (391-400 of 404) with videos related to

Sort By:
Pageof 41
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
Journal of Hepatology|November 24, 2015
FibroGENE: A gene-based model for staging liver fibrosisMohammed Eslam, Ahmed M Hashem, Manuel Romero-Gomez, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Nature Communications|March 6, 2015
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver diseaseMohammed Eslam, Ahmed M Hashem, Reynold Leung, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypesMohammed Eslam, Alessandra Mangia, Thomas Berg, et al.
Scientific Reports|February 7, 2019
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanismsRasha El Sharkawy, Ali Bayoumi, Mayada Metwally, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Pageof 41